First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer.
Allen Chung-Cheng HuangChi-Hsien HuangJia-Shiuan JuTzu-Hsuan ChiuPi-Hung TungChin-Chou WangChien-Ying LiuFu-Tsai ChungYueh-Fu FangYi-Ke GuoAllen Chung-Cheng HuangCheng-Ta YangPublished in: Therapeutic advances in medical oncology (2021)
Compared with gefitinib/erlotinib, afatinib had a higher treatment efficacy and a lower secondary T790M positivity in a large, real-world cohort of Asian patients with EGFR-mutated NSCLC.